Novacium décroche une première commande de plus de 100 packs batteries AA NOVA pour équiper un drone intercepteur d’Alta Ares, acteur européen de la lutte anti-drones sélectionné par la DGA

Novacium, 36.8%-owned by HPQ Silicon, received its first commercial order from Alta Ares for more than 100 AA NOVA 6S3P, 15,000mAh silicon-anode battery packs for the X-Lock counter-drone, following successful July 2026 testing of 10 prototypes. The packs, due for delivery by end-September, are lighter than Alta Ares' reference battery while maintaining at least equivalent performance; each pack uses 18 GEN3 5,000mAh cells capable of 25C discharge, or up to 125A per cell. The order validates Novacium's silicon-anode technology in a defense application and could lead to a recurring supply agreement, although no contract value or detailed weight savings were disclosed.

Analysis

For HPQ, the equity implication is less the initial order value—which is immaterial to a micro-cap issuer—and more whether Novacium can convert a custom-engineering win into a qualified recurring program. The critical commercial hurdle is repeatability: defense customers will value cycle life, safety under high-discharge use, field reliability, and delivery consistency at least as much as initial energy-density claims. Because HPQ owns only 36.8% of Novacium, any eventual revenue contribution is economically diluted and the market should not capitalize a defense-platform narrative before terms, volumes, and Novacium’s manufacturing economics are disclosed.

The near-term catalyst is a successful in-service evaluation and evidence of a follow-on framework order over the next 1-3 months; that would validate a transition from prototype-led revenue to program revenue. The main risk is that the disclosed mass advantage is unquantified and may arise partly from pack engineering rather than a defensible cell-material moat, leaving established high-power cell suppliers able to compete on qualification history and scale. A further risk is working-capital strain: small bespoke defense lots can consume cash through inventory, testing, and certification before producing meaningful gross profit.

Contrarian view: the strategic-European-supply-chain angle is real, but it is likely already more valuable as a promotional narrative than as a near-term earnings driver. The more investable second-order beneficiary, if European defense-drone procurement broadens, may be scaled battery and power-electronics suppliers with certified production capacity rather than early-stage anode developers. HPQ becomes interesting only if it demonstrates that silicon-anode cells retain performance after repeated high-C discharge cycles and secures funded volume commitments rather than additional evaluations.

Key Decisions for Investors

• No core directional position in HPQ at current information quality; treat any near-term strength as event-driven until the company discloses order value, gross-margin profile, production capacity, and cash required to fulfill follow-on demand.
• Set a 1-3 month HPQ catalyst alert for a binding multi-year or minimum-volume supply agreement, ideally with disclosed unit economics or prepayments. A follow-on order without volume, pricing, or qualification data is insufficient to revise earnings expectations materially.
• For existing HPQ exposure, reduce if the stock rerates materially on the announcement alone without a corresponding update on cycle-life testing, failure rates, manufacturing yield, or financing; these are the metrics that would falsify the commercialization thesis.
• Monitor European defense-drone procurement and battery qualification awards over 6-18 months; consider broader defense exposure through established European primes such as Rheinmetall (RHM.DE) or Hensoldt (HAG.DE) rather than assuming HPQ captures program-scale economics.